Comparison · NCT02588833-be2e9ec9
Cohort 1 vs Cohort 2: Number of Subjects Receiving Red Blood Cell (RBC) Transfusions
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cohort 1 vs Cohort 2: Number of Subjects Receiving Red Blood Cell (RBC) Transfusions. Trial comparisons, record NCT02588833-be2e9ec9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02588833-be2e9ec9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.333 | 0.0615 | 0.792 | wilson | |
| Risk in group 2 | 0.35 | 0.181 | 0.567 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0167 | -0.365 | 0.472 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.952 | 0.173 | 5.26 | log | |
| Odds ratio, group 1 over group 2 | 0.929 | 0.071 | 12.1 | log | |
| Number needed to treat, for one fewer participant with the outcome on Cohort 1 than on Cohort 2 | 60 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cohort 1 | Subjects received SC injections of pegcetacoplan 180 mg/day for up to 28 days. | 1 | 3 | OG000 |
| Group 2 | Cohort 2 | Subjects received SC injections or infusions of pegcetacoplan 270 mg/day for up to 364 days if entering the open-label extension study or, if entering Part 2C, until enrollment in the open-label extension study became available. If clinically indicated on the basis of response, the pegcetacoplan dosage could be increased up to 360 mg/day. | 7 | 20 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Receiving Red Blood Cell (RBC) Transfusions
- Description
- The number of on-study RBC transfusions were monitored throughout the treatment period.
- Time frame
- From Day 1 up to Day 533.
- Population
- The ITT population set included all subjects eligible to receive study drug and who received ≥1 dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.
- NCT number
- NCT02588833
- Phases
- PHASE1
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Pegcetacoplan
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Results first posted
- 2021-01-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02588833?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02588833-be2e9ec9